Nyxoah (NYXH) said Tuesday it is actively addressing the validation of a process used with a component of its Genie obstructive sleep apnea treatment device at its US manufacturing site ahead of potential US Food and Drug Administration marketing approval.
The company said it is confident of completing the validation in the near term, with the application approval likely in Q2.
The FDA late last month issued an approvable letter with regard to Genio's pre-market approval application.
Nyxoah shares were up nearly 23% in recent premarket activity.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.